title: Management of relapsed and relapsed/refractory multiple myeloma.
abstract: Despite significant progress in the treatment of multiple myeloma (MM) over the past decade, this disease remains incurable and almost all patients ultimately experience relapse and become refractory to treatment over time. However, the outlook for patients with relapsed MM has improved markedly with the use of the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM.
authors: Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. JacobP_Laubach@DFCI.harvard.edu
authors: Jacob P
authors: JP
authors: Laubach
authors: Constantine S
authors: CS
authors: Mitsiades
authors: Anuj
authors: A
authors: Mahindra
authors: Marlise R
authors: MR
authors: Luskin
authors: Jacalyn
authors: J
authors: Rosenblatt
authors: Irene M
authors: IM
authors: Ghobrial
authors: Robert L
authors: RL
authors: Schlossman
authors: David
authors: D
authors: Avigan
authors: Noopur
authors: N
authors: Raje
authors: Nikhil C
authors: NC
authors: Munshi
authors: Kenneth C
authors: KC
authors: Anderson
authors: Paul G
authors: PG
authors: Richardson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D012008:Recurrence